Association between adherence to Palivizumab and the incidence of Respiratory Syncytial Virus -associated outcomes in the Canadian Registry
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- 02 Nov 2017 New trial record